Modeling cancer immunotherapy: Assessing the effects of lymphocytes on cancer cell growth and motility

Physica A: Statistical Mechanics and its Applications

Volumn 392, Issue 10, 2013, Pages 2415-2425

  Ramos, R A ^a   Zapata, Jair ^a   Condat, C A ^b   Deisboeck, Thomas S ^c  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer growth; Cell blockade; Immunotherapy; Lymphocytes; Tumor model

Indexed keywords

CELL PROLIFERATION; DISEASES; IMMUNE SYSTEM; LYMPHOCYTES;

CANCER GROWTH; CANCER IMMUNOTHERAPY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVITY; MESOSCOPIC MODELING; TUMOR CELL MIGRATION; TUMOR MODELS; TUMOR-IMMUNE SYSTEM INTERACTION;

TUMORS;

EID: 84875218575     PISSN: 03784371     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physa.2013.01.047     Document Type: Article

References (43)

1. H.W. Herr, and A. Morales History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story J. Urol. 179 2008 53 56
2. F.S. Hodi Improved survival with Ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 2010 711 723
3. D. Kirschner, and J.C. Panetta Modeling immunotherapy of the tumor-immune interaction J. Math. Biol. 37 1998 235 252
4. F. Nani, and H.I. Freedman A mathematical model of cancer treatment by immunotherapy Math. Biosci. 163 2000 159 199
5. O. Sotolongo-Costa, L. Morales Molina, D. Rodríguez Pérez, J.C. Antoranz, and M. Chacón Reyes Behavior of tumors under nonstationary therapy Physica D 178 2003 242 253
6. H.P. De Vladar, and J.A. González Dynamic response of cancer under the influence of immunological activity and therapy J. Theoret. Biol. 227 2004 335 348
7. A. D'Onofrio A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences Physica D 208 2005 220 235
8. L.G. De Pillis, W. Gu, and A.E. Radunskaya Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations J. Theoret. Biol. 238 2006 841 862
9. B. Piccoli, and F. Castiglione Optimal vaccine scheduling in cancer immunotherapy Physica A 370 2006 672 680
10. C. Cattani, and A. Ciancio Qualitative analysis of second-order models of tumor-immune system competition Math. Comp. Modelling 47 2008 1339 1355
11. L.G. De Pillis Mathematical model creation for cancer chemo-immunotherapy Comput. Math. Methods Med. 10 2009 165 184
12. J.A. Adam, and N. Bellomo A Survey of Models for Tumor-Immune System Dynamics 1997 Birkhäuser Boston
13. T.S. Deisboeck, and G.S. Stamatakos Multiscale Cancer Modeling 2011 Taylor & Francis Boca Raton
14. E.S. Norris, J.R. King, and H.M. Byrne Modelling the response of spatially structured tumours to chemotherapy: drug kinetics Math. Comp. Modelling 43 2006 820 837
15. M. Scalerandi, A. Romano, G.P. Pescarmona, P.P. Delsanto, and C.A. Condat Nutrient competition as a determinant for cancer growth Phys. Rev. E 59 1999 2206 2217
16. A.R. Kansal, S. Torquato, G.R. Harsh IV, E.A. Chiocca, and T.S. Deisboeck Simulated brain tumor growth dynamics using a three dimensional cellular automaton J. Theoret. Biol. 203 2000 367 382
17. S.C. Ferreira Jr, M.L. Martins, and M.J. Vilela Reaction-diffusion model for the growth of avascular tumor Phys. Rev. E 65 2002 021907 1-8
18. M. Scalerandi, B. Capogrosso Sansone, C. Benati, and C.A. Condat Competition effects in the dynamics of tumor cords Phys. Rev. E 65 2002 051918 1-10
19. D.G. Mallet, and L.G. De Pillis A cellular automata model of tumor-immune system interactions J. Theoret. Biol. 239 2006 334 350
20. L.G. De Pillis, D.G. Mallet, and A.E. Radunskaya Spatial tumor-immune modeling Comput. Math. Methods Med. 7 2006 159 176
21. S.A. Menchón, R.A. Ramos, and C.A. Condat Modeling subspecies and the tumor-immune system interaction: Steps towards understanding therapy Physica A 386 2007 713 719
22. D. Wodarz, and N.L. Komarova Computational Biology of Cancer 2005 World Scientific Singapore
23. G. Morstyn, and W. Sheridan Cell Therapy 1996 Cambridge UP Cambridge, UK
24. V.T. DeVita, S. Hellman, and S.A. Rosenberg Principles and Practice of Oncology 2005 Lippincott Williams & Wilkins Philadelphia
25. S.A. Rosenberg The emergence of modern cancer immunotherapy Ann. Surg. Oncol. 12 2005 1 3
26. M.S. Meltzer, M.M. Stevenson, and E.J. Leonard Characterization of macrophage chemotaxins in tumor cell cultures and comparison with lymphocyte-derived chemotactic factors Cancer Res. 37 1977 721 725
27. N. Delens, E. Torreele, H. Savelkool, P. de Baetselier, and L. Bouwens Tumor-derived transforming growth factor-β 1 and interleukin-6 are chemotactic for lymphokine-activated killer cells Int. J. Cancer 57 1994 696 700
28. A.M. Hicks Transferable anticancer innate immunity in spontaneous regression/complete resistance mice Proc. Natl. Acad. Sci. USA 103 2006 7753 7758
29. A. Brú, S. Albertos, J.A. LópezGarcía-Asenjo, and I. Brú Pinning of tumoral growth by enhancement of immune response Phys. Rev. Lett. 92 2004 238101 1-4
30. C.A. Condat, B. CapogrossoSansone, P.P. Delsanto, and M. Scalerandi Modeling cancer growth Rec. Res. Dev. Biophys. Chem. 2 2001 53 69
31. S.A. Menchón, and C.A. Condat Cancer growth: Predictions of a realistic model Phys. Rev. E 78 2008 022901 1-4
32. B. Capogrosso Sansone, P.P. Delsanto, M. Magnano, and M. Scalerandi Effects of anatomical constraints on tumor growth Phys. Rev. E 64 2001 021903 1-8
33. S.A. Menchón, and C.A. Condat Modeling tumor cell shedding Eur. Biophys. J. 38 2009 479 485
34. P.P. Delsanto, M. Griffa, C.A. Condat, S. Delsanto, and L. Morra Bridging the gap between mesoscopic and macroscopic models: the case of multicellular tumor spheroids Phys. Rev. Lett. 94 2005 148105 1-4
35. E.J. Goetzl, A.H. Tashjian Jr, R.H. Rubin, and K.F. Austen Production of a low molecular weight eosinophil polymorphonuclear leukocyte chemotactic factor by anaplastic squamous cell carcinomas of human lung J. Clin. Investigation 61 1978 770 780
36. J. Van Damme, P. Proost, J.-P. Lenaerts, and G. Opdenakker G Structural and functional identification of two human, tumor derived, monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family J. Exp. Med. 176 1992 59 65
37. A. Wiedemann, D. Depoil, M. Faroudi, and S. Valitutti Cytotoxic T Lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses Proc. Natl. Acad. Sci. USA 103 2006 10985 10990
38. D.E. Speiser, and P. Romero Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity Semin. Immunol. 22 2010 144 154
39. B.D. Curti Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients J. Immunother. Emphasis Tumor Immunol. 19 1996 296 308
40. R.E. Merchant, D.W. McVicar, L.H. Merchant, and H.F. Young Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial J Neurooncol. 12 1992 75 83
41. J.D. Murray Mathematical Biology, Vol. I third ed. 2002 Springer New York
42. E. Beretta, and Y. Kuang Geometric stability switch criteria in delay differential systems with delay dependent parameters SIAM J. Math. Anal. 33 2002 1144 1165
43. A. d'Onofrio, F. Gatti, P. Cerrai, and L. Freschi Delay-induced oscillatory dynamics of tumour-immune system interaction Math. Comp. Modelling 51 2010 572 591